Bone Therapeutics
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Pha… Read more
Bone Therapeutics (0R55) - Total Assets
Latest total assets as of June 2025: €4.50 Million EUR
Based on the latest financial reports, Bone Therapeutics (0R55) holds total assets worth €4.50 Million EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bone Therapeutics - Total Assets Trend (2011–2024)
This chart illustrates how Bone Therapeutics’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bone Therapeutics - Asset Composition Analysis
Current Asset Composition (December 2024)
Bone Therapeutics's total assets of €4.50 Million consist of 34.5% current assets and 65.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 8.3% |
| Accounts Receivable | €1.01 Million | 21.3% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.00K | 0.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Bone Therapeutics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bone Therapeutics's current assets represent 34.5% of total assets in 2024, a decrease from 86.7% in 2011.
- Cash Position: Cash and equivalents constituted 8.3% of total assets in 2024, down from 36.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 21.3% of total assets.
Bone Therapeutics Competitors by Total Assets
Key competitors of Bone Therapeutics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
Bone Therapeutics - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Bone Therapeutics generates 0.06x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Bone Therapeutics is currently not profitable relative to its asset base.
Bone Therapeutics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.53 | 0.40 | 1.00 |
| Quick Ratio | 0.53 | 0.40 | 1.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-3.46 Million | € -3.90 Million | € -52.00K |
Bone Therapeutics - Advanced Valuation Insights
This section examines the relationship between Bone Therapeutics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -50.4% |
| Total Assets | €4.74 Million |
| Market Capitalization | $24.13K USD |
Valuation Analysis
Below Book Valuation: The market values Bone Therapeutics's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bone Therapeutics's assets decreased by 50.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bone Therapeutics (2011–2024)
The table below shows the annual total assets of Bone Therapeutics from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €4.74 Million | -50.39% |
| 2023-12-31 | €9.56 Million | -67.40% |
| 2022-12-31 | €29.32 Million | +48.31% |
| 2021-12-31 | €19.77 Million | -20.39% |
| 2020-12-31 | €24.84 Million | +10.91% |
| 2019-12-31 | €22.39 Million | -13.05% |
| 2018-12-31 | €25.75 Million | +2.30% |
| 2017-12-31 | €25.17 Million | -34.76% |
| 2016-12-31 | €38.59 Million | -23.42% |
| 2015-12-31 | €50.38 Million | +108.18% |
| 2014-12-31 | €24.20 Million | +88.92% |
| 2013-12-31 | €12.81 Million | -11.15% |
| 2012-12-31 | €14.42 Million | -4.22% |
| 2011-12-31 | €15.05 Million | -- |